Soft Tissue Sarcoma in Dogs: Tumor Grades and Treatment

Soft tissue sarcomas are a family of tumors that arise from connective tissues in dogs, including fat, muscle, fibrous tissue, and the sheaths around nerves and blood vessels. They rank among the more common solid tumors in dogs, typically showing up as firm, fleshy masses under the skin or within deeper tissue layers. The good news is that most behave in a locally aggressive but slow-to-spread pattern, meaning surgery alone can be curative in many cases. But tumor grade, location, and surgical margins all play major roles in how the story unfolds for any individual dog.

What Soft Tissue Sarcomas Actually Are

The term “soft tissue sarcoma” is an umbrella that covers a surprisingly wide range of tumor types. Rather than a single disease, it describes a group of cancers that share certain clinical behaviors while originating from different cell lineages. A pathologist examining these tumors under a microscope can see considerable variety. In one comparative study, the most frequent pattern resembled low-grade spindle cell sarcomas with fibroblastic or myofibroblastic features. Others resembled liposarcomas, myxofibrosarcomas, or undifferentiated sarcomas.¹ Despite these different origins, veterinary oncologists group them together because they tend to behave similarly: they grow as pseudo-encapsulated masses that infiltrate surrounding tissue with microscopic tendrils, making clean removal tricky.

You might hear your vet mention specific names like fibrosarcoma, peripheral nerve sheath tumor, myxosarcoma, or liposarcoma. These are all subtypes that fall under the soft tissue sarcoma umbrella. The subtype matters for the pathologist and can influence the prognosis slightly, but the treatment approach is broadly the same across the group.

What Owners Typically Notice

Most soft tissue sarcomas present as a lump that the owner finds while petting or grooming their dog. The mass is usually located on the limbs, trunk, or head, sitting just beneath the skin or slightly deeper. These tumors tend to be firm and attached to underlying tissue rather than freely movable. They grow at a variable pace, with some enlarging slowly over months and others seemingly appearing quickly.

Dogs rarely show pain or illness from these tumors in the early stages. That lack of obvious symptoms is part of what makes them sneaky. A dog can carry a growing mass for weeks without any change in appetite, energy, or behavior, which means owners sometimes delay a vet visit because the lump “doesn’t seem to bother” the dog. Any new or growing lump on your dog warrants veterinary attention, even if your dog seems perfectly fine otherwise.

Getting a Diagnosis

The first step is usually a fine needle aspirate, where a vet inserts a small needle into the mass and collects cells for examination. This is quick and minimally invasive, but it has a notable limitation for soft tissue sarcomas. In one study, fine needle aspiration correctly identified the tumor type in only about 63% of soft tissue sarcoma cases, compared to 96% for mast cell tumors.² Soft tissue sarcomas shed cells poorly, and the cells they do release can look non-descript, making a definitive diagnosis from a needle sample alone hit-or-miss.

Because of this, a tissue biopsy, either an incisional biopsy (a small sample taken before the main surgery) or a full excisional biopsy (removing the entire mass), is often needed for a definitive diagnosis and grade. When the tumor is in a tricky location or when the vet needs to plan a complex surgery, advanced imaging comes into play. CT scans help map out the tumor’s boundaries relative to surrounding structures, supporting better preoperative planning.³ This is especially valuable for tumors lodged near joints, major blood vessels, or bones, where the surgical approach can make or break the outcome.

Tumor Grade and Why It Drives Everything

If there is one piece of information that matters more than anything else for predicting your dog’s outcome, it is the histologic grade. Pathologists assign a grade (I, II, or III) based on features they see under the microscope, including how abnormal the cells look, how fast they are dividing, and how much tissue death is present within the tumor. Of these features, the rate of cell division (mitotic rate) is particularly telling: it predicts both the likelihood of spread to distant sites and overall survival.⁴

Grade I tumors are the least aggressive. They tend to grow slowly, are unlikely to spread to other organs, and even when surgical margins are close, most will not come back. Grade II tumors occupy a middle ground with a moderate risk of local recurrence and a low but real possibility of metastasis. Grade III tumors are the most worrisome. They carry the highest rates of both recurrence and spread, with metastasis most likely to appear in the lungs.⁵ The jump in behavior between grade I and grade III is substantial enough that the same broad tumor type can have a very different prognosis depending on what the pathologist reports.

Surgery as the Primary Treatment

Wide surgical excision is the treatment of choice for most soft tissue sarcomas. The goal is to remove the tumor with a generous cuff of normal tissue around it, ideally achieving what pathologists call “clean” or “complete” margins. This matters because soft tissue sarcomas infiltrate beyond what you can see or feel. The pseudo-capsule that makes them appear well-contained is deceptive; microscopic tumor cells almost always extend into the tissue surrounding that capsule.

A meta-analysis pooling data from multiple studies found that about 10% of completely excised soft tissue sarcomas recurred locally, compared to roughly a third of those with incomplete margins.⁶ Complete margins reduced the risk of local recurrence by about 60% compared to incomplete margins. That finding has been confirmed across individual studies and is one of the most consistent results in veterinary surgical oncology.

But the story of margins is more nuanced than just “complete versus incomplete.” A study that tracked dogs for three years found that recurrence risk varied across three categories: dogs with tumor-free margins had about a 7% recurrence rate, those with close but not infiltrated margins had roughly a 23% rate, and those with truly infiltrated margins saw recurrence in about 41% of cases.⁷ In other words, not all “incomplete” margins are equally bad. A tumor that sits close to the margin but doesn’t touch it carries less risk than one where tumor cells are present right at the cut edge. This three-tier system gives vets and owners a more useful picture for deciding whether additional treatment is needed after surgery.

The practical challenge is that achieving wide margins isn’t always possible. A tumor wrapped around a limb, sitting over a bony prominence, or growing near a joint may not allow for the ideal 2-3 centimeters of surrounding tissue that surgeons prefer. In those situations, the team has to weigh the option of a more radical surgery (sometimes amputation) against less aggressive removal followed by adjunct treatments like radiation.

Radiation Therapy

Radiation is most commonly used after surgery when margins are incomplete or uncomfortably close, and it can also serve as a primary treatment when a tumor cannot be surgically removed. Traditional radiation protocols for soft tissue sarcomas typically involve multiple sessions (fractions) delivered over several weeks, aiming to destroy residual microscopic disease at the surgical site.

Stereotactic body radiotherapy (SBRT) is a newer approach that delivers high doses of radiation in just a few sessions, targeting the tumor with precision. A study of 52 dogs with measurable soft tissue sarcomas treated with SBRT found that about 30% showed a meaningful response, with three achieving complete tumor disappearance and eleven experiencing substantial shrinkage. The median overall survival was 228 days for the group as a whole, but dogs whose tumors responded to treatment survived a median of 475 days, more than double those that did not respond.⁸ Dogs with smaller tumors and earlier-stage disease tended to fare best, underscoring the value of not waiting too long before pursuing treatment.

Radiation does carry side effects. Skin irritation, hair loss, and tissue fibrosis in the treatment zone are common. Most of these are manageable and temporary, though late-onset fibrosis can occasionally cause chronic stiffness. The decision to add radiation usually involves balancing these side effects against the risk of the tumor coming back.

Chemotherapy and Metronomic Protocols

Traditional high-dose chemotherapy has generally been disappointing for soft tissue sarcomas in dogs. These tumors tend to be relatively resistant to standard intravenous chemotherapy agents, and the response rates are modest enough that chemo is not considered a first-line treatment for most cases. However, there is a growing body of evidence supporting a different strategy: metronomic chemotherapy.

Metronomic chemotherapy uses low, continuous doses of drugs rather than the high-dose pulses of traditional protocols. The idea is to target the blood supply feeding the tumor and modulate the immune environment around it, rather than trying to directly kill every cancer cell. One study combining low-dose cyclophosphamide with the anti-inflammatory drug piroxicam found that the combination significantly delayed tumor recurrence in dogs with incompletely excised soft tissue sarcomas, compared to dogs that received no post-surgical treatment.⁹ The drugs are given orally at home, the side-effect profile is much milder than traditional chemo, and the cost is relatively low. For many owners who cannot pursue radiation or repeat surgery, metronomic therapy offers a practical middle ground.

Electrochemotherapy and Newer Local Treatments

Electrochemotherapy (ECT) is a treatment that combines low doses of chemotherapy drugs with brief electrical pulses applied directly to the tumor. The electrical pulses temporarily open pores in the tumor cell membranes, dramatically increasing drug uptake at the tumor site while keeping systemic drug levels low. It has been gaining traction as an option for soft tissue sarcomas that are difficult to remove surgically or have recurred after prior treatment.

In a study of 30 dogs treated with ECT using bleomycin and cisplatin after marginal or incomplete surgery, roughly 87% had no evidence of recurrence during the follow-up period, with an estimated disease-free time exceeding 857 days for the group overall.¹⁰ A separate review evaluating ECT with bleomycin alone also concluded that the approach was safe and effective for local tumor control.¹¹ ECT is not yet widely available at every veterinary oncology center, but its relatively low toxicity and encouraging local control rates are drawing increasing interest.

Immunotherapy is another frontier under active investigation. Cancer vaccines, checkpoint inhibitors, and other immune-modulating strategies are being explored in dogs with soft tissue sarcomas, partly because dogs develop these tumors spontaneously and share environmental exposures with humans, making them useful research models.¹² Results are still preliminary, and no immunotherapy protocol has become standard of care for canine soft tissue sarcomas. But the pace of research is accelerating, and clinical trials are ongoing at several veterinary teaching hospitals.

What Genetic Research Is Revealing

Molecular profiling of canine soft tissue sarcomas has advanced rapidly in recent years, offering a window into what drives these tumors at the DNA level. One integrated analysis found that the most frequently mutated genes were TP53 and KMT2D, each altered in about one in five tumors. TP53 is a well-known tumor suppressor gene, and mutations disabling it are a hallmark of many cancers across species. KMT2D is involved in chromatin organization, essentially the packaging and regulation of DNA. Mutations in chromatin-related genes were found in the majority of tumors sampled.¹³

An earlier study examining p53 mutations and a related gene called MDM2 in canine sarcomas found p53 mutations in about 20% of cases and MDM2 amplification in roughly 11%. The two alterations showed a reciprocal pattern: tumors that carried one rarely carried the other, suggesting these are two different routes to disabling the same protective pathway.¹⁴

Perhaps the most actionable molecular finding involves fusion genes combining collagen genes with the platelet-derived growth factor B gene (PDGFB). A subset of canine sarcomas carry these fusions, which drive dramatically increased PDGFB signaling. This is significant because the same type of fusion has been identified in a subset of human sarcomas, where it predicts sensitivity to drugs that inhibit the PDGF receptor.¹⁵ This raises the possibility that targeted therapies like imatinib, already used in human oncology, could benefit dogs whose tumors harbor these specific genetic changes. Routine molecular testing for canine sarcomas is not yet standard practice, but the groundwork is being laid for an era where treatment choices are guided by the genetic profile of the individual tumor.

Dogs as Research Models for Human Sarcomas

One of the reasons canine soft tissue sarcoma research has attracted funding and attention is the overlap with human disease. Dogs develop these tumors spontaneously, live in the same environments as their owners, and display genetic diversity across breeds that mirrors population-level variation in humans.¹⁶ Laboratory mice, by contrast, develop tumors only when they are genetically engineered or deliberately implanted with cancer cells, which limits how well those models reflect real-world disease progression and treatment responses.

The histologic similarities between canine and human soft tissue sarcomas are striking. Many of the same tumor subtypes that pathologists recognize in humans have direct counterparts in dogs, including spindle cell sarcomas, liposarcomas, myxofibrosarcomas, and undifferentiated sarcomas.¹⁷ The molecular parallels, particularly the shared PDGFB fusions and TP53 pathway disruptions, further strengthen the case that studying canine sarcomas can generate insights that translate to human patients. For dog owners, this comparative research angle has a practical upside: it channels additional resources into understanding and treating a cancer that affects their pets, because the findings have value for human medicine as well.

Breed Predisposition and What Causes These Tumors

Soft tissue sarcomas can occur in any breed and at any age, but they are diagnosed more frequently in middle-aged to older dogs and in larger breeds. Golden Retrievers, Labrador Retrievers, Boxers, and flat-coated Retrievers appear in the veterinary literature as overrepresented breeds, though the tumors are by no means limited to these populations. The reasons for breed predisposition are not fully understood but likely involve inherited variations in tumor suppressor genes and DNA repair pathways.

As for environmental causes, no single culprit has been definitively identified. Injection-site sarcomas, well documented in cats, are extremely rare in dogs, so vaccination is not considered a meaningful risk factor. Prior radiation exposure at a site can theoretically predispose to sarcoma development, but this is uncommon in clinical practice. For most dogs diagnosed with a soft tissue sarcoma, the honest answer to “why did this happen?” is that we do not know. The spontaneous nature of these tumors, arising without an obvious external trigger, is actually one of the features that makes them useful models for studying cancer biology more broadly.

Living with the Diagnosis

A soft tissue sarcoma diagnosis understandably alarms dog owners, but for many dogs, especially those with low-grade tumors that can be completely excised, the long-term outlook is genuinely good. The decision tree after diagnosis depends on grade, location, and whether clean surgical margins can be achieved. A grade I tumor removed with wide margins may need nothing more than periodic monitoring with physical exams and chest X-rays. A high-grade tumor with incomplete margins may call for radiation, metronomic chemotherapy, or both.

Monitoring after treatment typically involves follow-up exams every three months for the first year or two, then every six months. The vet will palpate the surgical site for any sign of regrowth and may recommend periodic chest radiographs to screen for lung metastasis, particularly for grade II and III tumors. Recurrence at the original site is more common than distant spread for the group as a whole, so feeling the area regularly at home and reporting any new firmness promptly gives your vet the best chance of catching a problem early, when a second surgery or radiation can still be effective.